Pursuit of cures, backed by collaboration
Teaming up to take research discoveries from bench to bedside
Complex diseases require new, innovative approaches. Mayo Clinic is actively developing transformative processes that can bring novel and better cures to patients. Investment in these processes and products is needed to produce cures for patients at greater speed and scale.
Mayo Clinic Ventures, Mayo Clinic’s technology commercialization arm responsible for taking inventions and translating them into commercial products, works diligently to move solutions quickly from bench to bedside. Involving both internal and external stakeholders is crucial to success.
Finding answers to challenging conditions
These new technologies show promise and the importance of a collaborative approach:
Endoscopic treatment of obesity
An innovative medical device developed at Mayo Clinic by Barham Abu Dayyeh, M.D., and team for the treatment of type II diabetes, obesity and metabolic disease through a minimally invasive endoscopic procedure is finding promise for patients.
The device supports an outpatient procedure to treat obesity. The method recently received De Novo classification (which grants marketing) from the Food and Drug Administration (FDA), and recent Mayo Clinic findings are published in The Lancet, which ranks first among all medical journals globally.
This technology’s advancement is made possible in large part by the productive partnership between Mayo Clinic Ventures, Research, the Department of Surgery and the Division of Gastroenterology.
Cancer treatment innovation
Based on encouraging results in early clinical trials, Mayo Clinic Ventures collaborated with a biotechnology company to lead the development of an antibody-drug-nanoparticle albumin-bound (nab) immune complex (ADNIC) technology invented by Svetomir Markovic, M.D., Ph.D., Wendy Nevala and team for treating a spectrum of cancers. The technology platform is protected by an intellectual property portfolio comprised of 17 patent families, 32 patents granted to date with life through at least 2035, and another 135 patents pending.
The ADNIC technology is currently in clinical trials for multiple products in a variety of cancers, including ovarian, endometrial, and multiple lymphoma subtypes.
Gene therapy for rare, fatal genetic disease
Propionic acidemia, a rare and fatal genetic disease that often sickens babies in their first days of life, occurs in 1 in 100,000 live births in the U.S. There is no cure, with current treatment options limited and not delivering the long-lasting benefits that patients and their families seek.
Michael Barry, Ph.D., and his team with the Center for Individualized Medicine have developed a technique to replace the defective genes that cause the disease. The therapy has been granted FDA Orphan Drug and Rare Pediatric Disease designations.
Mayo Clinic will continue to transform health care proactively through disease interception, early detection and treatments. Cures for rare and complex conditions is an endless pursuit.
Continuing the search for answers
Mayo Clinic will continue to work to transform health care through early disease detection and innovative treatments. Finding cures for rare and complex conditions is a never-ending pursuit.
Mayo Clinic has research and financial interest in the technologies referenced in this article. Mayo will use any revenue it receives to support its not-for-profit mission in patient care, education and research.
Share this story
A version of the story was originally published in Mayo Clinic’s Discovery Edge.
Mayo Clinic and Drs. Peng and Russell have a financial interest related to the NIS imaging technology referenced in this article. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education and research.